新型冷却激光局灶治疗前列腺癌的早期试验结果
PFLT-PC 是一项单臂 II 期试验,纳入 100 例局限性前列腺癌患者,评估 ProFocal 冷却激光局灶治疗的安全性及短期肿瘤学结果。3 个月治疗区活检显示 84% 无 ISUP 分级≥2 的前列腺癌,勃起功能障碍发生率为 12%,无其他功能指标下降。结论认为该治疗短期成功率较高、并发症少,但缺乏对照组且随访时间短。
要点
- 3 个月治疗区活检中 84% 未发现 ISUP 分级≥2 的前列腺癌。
- 勃起功能障碍发生率为 12%,SHIM 和 EPIC 性功能评分平均下降 15%。
- EPIC 泌尿领域评分下降 4.5%,其他功能指标未见下降。
核心结论
- ProFocal 冷却激光局灶治疗在 3 个月时提供 84% 的治疗成功率且并发症少。
研究设计与样本
- 单臂 II 期临床试验(PFLT-PC),在澳大利亚 Nepean 医院招募 100 例局限性前列腺癌患者。
- 纳入标准为 PSA≤15 ng/mL、T 分期≤T2c、ISUP 评分 2-3 且与 mpMRI 可见病灶一致。
主要发现
- 中位年龄 66 岁,中位 PSA 5.9 ng/mL,中位前列腺体积 39 mL,中位 MRI 病灶体积 0.84 mL。
- 中位治疗时间 60 分钟。
- 3 个月治疗区活检中 84% 无 ISUP 分级≥2 的前列腺癌。
- 勃起功能障碍发生率为 12%,SHIM 和 EPIC 性功能领域评分平均下降 15%。
- EPIC 泌尿领域评分下降 4.5%,其他功能指标未见下降。
临床怎么用
- 对于符合条件的局限性前列腺癌患者,可考虑 ProFocal 冷却激光局灶治疗作为短期治疗选择。
- 治疗后需通过 mpMRI 和活检评估肿瘤学结局,并监测性功能和泌尿功能变化。
局限性
- 缺乏对照组。
- 随访时间短。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To determine the short-term oncological results and safety of the ProFocal Laser Therapy for Prostate Tissue Ablation (PFLT-PC) trial, the first phase II clinical trial of ProFocal® (Medlogical Innovations, Sydney, Australia), a novel, cooled laser focal therapy (cLFT) device for prostate cancer (PCa) treatment. PATIENTS AND METHODS: Men with localised PCa, prostate-specific antigen (PSA) level ≤15 ng/mL, T stage ≤T2c, International Society of Urological Pathology (ISUP) score 2-3 concordant with multiparametric magnetic resonance imaging (mpMRI) visible disease were recruited for this trial (Australian and New Zealand Clinical Trial Registry [ACTRN]12618001774213p) at Nepean Hospital, Australia. The cLFT was performed under general anaesthesia as a day procedure. Primary outcome was adequacy of tissue ablation assessed by mpMRI within 72 h and biopsy at 3 months. Secondary outcomes of functional measures were assessed using validated questionnaires (International Prostate Symptom Score, Sexual Health Inventory for Men [SHIM], Expanded Prostate cancer Index Composite [EPIC], 12-item Short-Form Health Survey). Complications and adverse events within 90 days were reported using Clavien-Dindo classification grading. RESULTS: A total of 100 patients were recruited. The median (interquartile range [IQR]) age was 66 (60-72) years, PSA level 5.9 (3.9-7.6) ng/mL, prostate volume 39 (30-51) mL and MRI lesion volume 0.84 (0.57-1.2) mL. The median (IQR) treatment time was 60 (47-70) min. In all, 84% had no ISUP Grade Group ≥2 PCa in their 3-month treatment zone biopsies. Erectile dysfunction was reported in 12% of the men, with a 15% mean decline in the SHIM and EPIC-sexual domains scores. There was a 4.5% decrease on EPIC-urinary domain scores. There was no decline in any other functional measures. This study's main limitations were the absence of a control group and the short follow-up. CONCLUSIONS: The PFLT-PC trial demonstrates that at 3 months, cLFT using the ProFocal device provides an 84% treatment success with low morbidity.
引用
- Kam J, Hanna B, Jackson S, et al. Focal therapy using a novel cooled laser device for prostate cancer: early trial results. BJU Int. 2026. PMID: 41601270. doi:10.1111/bju.70150
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。